메뉴 건너뛰기
.. 내서재 .. 알림
소속 기관/학교 인증
인증하면 논문, 학술자료 등을  무료로 열람할 수 있어요.
한국대학교, 누리자동차, 시립도서관 등 나의 기관을 확인해보세요
(국내 대학 90% 이상 구독 중)
로그인 회원가입 고객센터 ENG
주제분류

추천
검색

논문 기본 정보

자료유형
학술저널
저자정보
Ryu Ji Hwa (School of Pharmacy, Sungkyunkwan University, Suwon, Korea.Department of Development, SK Bioscience, Seongnam, Korea.) Choi Ahhyung (School of Pharmacy, Sungkyunkwan University, Suwon, Korea.Harvard-MIT Center for Regulatory Science, Harvard Medical School, Boston, MA, USA.) Woo Jieun (Department of Biohealth Regulatory Science, Sungkyunkwan University, Suwon, Korea.) Lee Hyesung (School of Pharmacy, Sungkyunkwan University, Suwon, Korea.Department of Biohealth Regulatory Science, Sungkyunkwan University, Suwon, Korea.) Kim Jinkwon (Department of Neurology, Yongin Severance Hospital, Yonsei University College of Medicine, Yongin, Korea.) Yoo Joonsang (Department of Neurology, Yongin Severance Hospital, Yonsei University College of Medicine, Yongin, Korea.) Shin Ju-Young (School of Pharmacy, Sungkyunkwan University, Suwon, Korea.Department of Biohealth Regulatory Science, Sungkyunkwan University, Suwon, Korea.Samsung Advanced Institute for Health Sciences)
저널정보
대한의학회 Journal of Korean Medical Science Journal of Korean Medical Science Vol.39 No.24
발행연도
2024.6
수록면
1 - 12 (12page)
DOI
10.3346/jkms.2024.39.e190

이용수

표지
📌
연구주제
📖
연구배경
🔬
연구방법
🏆
연구결과
AI에게 요청하기
추천
검색

초록· 키워드

오류제보하기
Background: Cancer patients have an increased risk of cardiovascular outcomes and are susceptible to coronavirus disease 2019 (COVID-19) infection. We aimed to assess the cardiovascular safety of COVID-19 vaccination for cancer patients in South Korea. Methods: We conducted a self-controlled case series study using the K-COV-N cohort (2018– 2021). Patients with cancer aged 12 years or older who experienced cardiovascular outcomes were identified. Cardiovascular outcomes were defined as myocardial infarction, stroke, venous thromboembolism (VTE), myocarditis, or pericarditis, and the risk period was 0–28 days after receiving each dose of COVID-19 vaccines. A conditional Poisson regression model was used to calculate the incidence rate ratio (IRR) with 95% confidence interval (CI). Results: Among 318,105 patients with cancer, 4,754 patients with cardiovascular outcomes were included. The overall cardiovascular risk was not increased (adjusted IRR, 0.99 [95% CI, 0.90–1.08]) during the whole risk period. The adjusted IRRs of total cardiovascular outcomes during the whole risk period according to the vaccine type were 1.07 (95% CI, 0.95–1.21) in the mRNA vaccine subgroup, 0.99 (95% CI, 0.83–1.19) in the ChAdOx1 nCoV-19 vaccine subgroup, and 0.86 (95% CI, 0.68–1.10) in the mix-matched vaccination subgroup. However, in the analysis of individual outcome, the adjusted IRR of myocarditis was increased to 11.71 (95% CI, 5.88–23.35) during the whole risk period. In contrast, no increased risk was observed for other outcomes, such as myocardial infarction, stroke, VTE, and pericarditis. Conclusion: For cancer patients, COVID-19 vaccination demonstrated an overall safe profile in terms of cardiovascular outcomes. However, caution is required as an increased risk of myocarditis following COVID-19 vaccination was observed in this study.

목차

등록된 정보가 없습니다.

참고문헌 (0)

참고문헌 신청

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!

최근 본 자료

전체보기

댓글(0)

0